Navigation Links
A new sensor to detect lung cancer from exhaled breath
Date:12/23/2011

Some illnesses such as lung and stomach cancer or liver diseases which, due to the difficulty of diagnosis, have symptoms that are often confused with routine disorders. Therefore, in most cases, the disease is only detected at an advanced stage. New methods for early detection are being investigated as an urgent need.

Tecnalia, through the Interreg project Medisen, is contributing to develop biosensors capable of detecting the presence of tumour markers of lung cancer in exhaled breath. This is possible because of the changes produced within the organism of an ill person, changes reflected in the exhaled breath of the patient and which enable determining the presence of this type of marker during the initial stages of the disease.

Patients with lung cancer, treated in the Section of Medical Oncology of the Institute of Onco-Haemathology of the Donostia Hospital (IDOH) have collaborated in this phase of the project. For that, the Ethic Committee of the Clinical Research of Euskadi (CEIC) gave the authorization to the Instituto Biodonostia for the clinical trials

Human breath, whether from a healthy or ill person, is comprised of a hundreds of organic compounds: acetone, methanol, butanol, hydrocarbons, amongst others. There is not a single specific component in the exhaled breath capable of acting as a marker for the diagnosis of lung cancer. A range of biomarkers and its combination should be selected. The compounds of interest are generally to be found at 1-20 parts per billion (ppb) in healthy human breath but can be increased 10-100-fold in the breath of sick patients. In order to be able to detect these changes the development of novel materials was required.

During the first phase of the project, breath samples were collected by the hospital staff by a breath collecting device. A detailed analysis of the most representative compounds present in the breath samples has been carried out and the family or families of compounds required to act as markers for the presence of lung cancer selected. Organic compounds have been analysed using gas chromatograph/mass spectrometry analysis (GC/MS). Then, the GC/MS results of breath tests have been analysed by statistical and structural algorithms to discriminate and identify "healthy and "cancerous" patterns that really provide information for the design of the sensor.

In parallel, novel materials for the detection of the selected organic compounds have been developed by Tecnalia in order to increase the sensitivity of the devices. Participating together with Tecnalia in this project were the Instituto de Tecnologas Qumicas Emergentes de La Rioja (Inter-Qumica) designing the sensor device and the University of Perpignan (France) testing the novel materials.

As a conclusion, the biosensors will facilitate the diagnosis of certain diseases; mainly those located in the lungs, at the initial stages of the illness, which could increase considerably the chances of survival.


'/>"/>

Contact: Irati Kortabitarte
i.kortabitarte@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. UV light controls antibodies, improves biosensors
2. Nobel Laureate Bruce Beutler on molecular sensors as a trigger for autoimmune disease
3. Stanford researchers build transparent, super-stretchy skin-like sensor
4. City College of New York-led research could lead to wearable sensors for the blind
5. Researchers building new sensor that could stop falls by elderly, before they happen
6. Mobile Sensors Track Health of Elderly in Pilot Test
7. Improving DNA sequencing: Sponge-like biosensor crams enormous power into tiny space
8. Tests show new biosensor can guide environmental clean-ups
9. Get a whiff of this: Low-cost sensor can diagnose bacterial infections
10. Self-powered, blood-activated sensor detects pancreatitis quickly and cheaply
11. Low-cost wireless sensor networks open new horizons for the Internet of things
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... California Senate Bill (SB) 863, signed into law in 2012, ... and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a ... study, medical payments per claim in California decreased 4 percent in 2013 and then ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne ... offices headquartered in Hamilton County, is embarking on a charity drive with the ... finding new homes for orphaned or neglected senior dogs in the Cincinnati region, ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial consulting services to residential and commercial clients in the northern Alabama ... support for Nobis Works. , Since 1977, Nobis Works has built a network ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting ... MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone in ... it’s needed. , A 2’ x 4’ model features four modes: reading, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (“Presence”) for a purchase price of approximately $17.4 million (net of the ... revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
Breaking Medicine Technology: